A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation

Handgretinger, 2001, Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children, Bone Marrow Transplant, 27, 777, 10.1038/sj.bmt.1702996 Lang, 2003, Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia, Blood, 101, 1630, 10.1182/blood-2002-04-1203 Gordon, 2002, A large-scale method for T cell depletion: towards graft engineer ing of mobilized peripheral blood stem cells, Bone Marrow Transplant, 30, 69, 10.1038/sj.bmt.1703619 Ho, 2001, The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation, Blood, 98, 3192, 10.1182/blood.V98.12.3192 Curtis, 1999, Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study, Blood, 94, 2208 Babcock, 1998, EBV persistence in memory B cells in vivo, Immunity, 9, 395, 10.1016/S1074-7613(00)80622-6 Paya, 1999, Epstein-Barr virus-induced posttransplant lymphoproliferative disorders ASTS/ASTP EBV-PTLD [Task Force and The Mayo Clinic Orga nized International Consensus Development Meeting], Transplantation, 68, 1517, 10.1097/00007890-199911270-00015 van Esser, 2002, Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation, Blood, 99, 4364, 10.1182/blood.V99.12.4364 van Esser, 2001, Epstein -Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lympho-proliferative disease following T-cell-depleted SCT, Blood, 98, 972, 10.1182/blood.V98.4.972 Hale, 1998, Risks of developing Epstein -Barr virus- related lymphoproliferative disorders after T-cell-depleted marrow transplants [CAMPATH Users], Blood, 91, 3079, 10.1182/blood.V91.8.3079.3079_3079_3083 Cavazzana-Calvo, 1998, Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non- identical T-depleted bone marrow transplantation, Br J Haematol, 103, 543, 10.1046/j.1365-2141.1998.00972.x Dreger, 2000, A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia, Exp Hematol, 28, 1187, 10.1016/S0301-472X(00)00524-5 Benkerrou, 1998, Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoprolifera tive disorder: prognostic factors and long-term outcome, Blood, 92, 3137, 10.1182/blood.V92.9.3137 Cavazzana-Calvo, 1998, Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non- identical T-depleted bone marrow transplantation, Br J Haematol, 103, 543, 10.1046/j.1365-2141.1998.00972.x Gordon, 2002, A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells, Bone Marrow Transplant, 30, 69, 10.1038/sj.bmt.1703619 Andre-Schmutz, 2002, Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study, Lancet, 360, 130, 10.1016/S0140-6736(02)09413-8 Aversa, 1999, Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia, J Clin Oncol, 17, 1545, 10.1200/JCO.1999.17.5.1545 Ruggeri, 2001, Cellular therapy: exploiting NK cell alloreactivity in transplantation, Curr Opin Hematol, 8, 355, 10.1097/00062752-200111000-00007 Farag, 2002, Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect, Blood, 100, 1935, 10.1182/blood-2002-02-0350 Ruggeri, 1999, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, Blood, 94, 333, 10.1182/blood.V94.1.333.413a31_333_339 Velardi, 2002, NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol, 23, 438, 10.1016/S1471-4906(02)02284-6 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440